Apple Turns 50: From Garage Startup to AI Crossroads 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
MELBOURNE, Australia, Nov. 29, 2016 -- Immuron Limited (ASX:IMC) is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of $1.6 million for eligible research and development expenditure incurred during the 2016 Financial Year.
This refund reflects the Company’s $3.6M investment in research and development expenditure during the 2016 Financial Year toward the development of the Company’s pipeline programs including IMM-124E in NASH and ASH, IMM-529 in C. difficile, as well as the continuous development of the Company’s existing Travelan/Protectyn programs.
Immuron CEO Mr Thomas Liquard commented:
“We are grateful that the Australian Government is such a strong supporter of the development of early-stage biotechnology companies through the R&D Tax Concession initiative scheme. This cash refund scheme has allowed Immuron the opportunity to accelerate the clinical development timelines for a number of its high-value pipeline programs.”
The Company anticipates that its ongoing research and development programs, including components of its fatty-liver disease programs, will continue to be eligible for the Research and Development Income Tax Concession refund incentive program for the 2017 financial year.
About Immuron:
Immuron Ltd (ASX:IMC); (OTCQB: IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
For more information, visit: http://www.immuron.com/
Company Contact: Thomas Liquard Chief Executive Officer Ph: +61 (0)3 9824 5254 [email protected] Immuron Media Relations: John Beveridge Monsoon Communications Ph: +61 (0)3 9620 3333 [email protected]
